Business
SAB Biotherapeutics Announces Publication of Preclinical Data Demonstrating SAB-185 Effectively Neutralizes SARS-CoV-2 Variants
Findings Published in Human Vaccines & Immunotherapeutics Show SAB-185 Neutralizes Virus Strains Containing Substitutions Present in Variants of Concern
About this update from Sab Biotherapeutics, Inc.
[{"type":"text","content":"\nFindings Published in Human Vaccines & Immunotherapeutics Show SAB-185 Neutralizes Virus Strains Containing Substitutions Present in Variants of Concern\n\n SIOUX FALLS, S.D.--(BUSINESS WIRE)--\nSAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibody therapeutics, today announced the publication of in vitro data showing that SAB-185, the company’s therapeutic candidate for the treatment of COVID-19 virus infections, demonstrated effective neutralization against SARS-CoV-2 virus strains containing the genetic substitutions present in recent variants of concern. The article, “Human immunoglobulin from transchromosomic bovines hyperimmunized with SARS-CoV-2 spike antigen efficiently neutralizes viral variants,” was published in the current edition of Human Vaccines & Immunotherapeutics. SAB-185, a differentiated high-potency therapeutic candidate for COVID-19, is currently being assessed in a Phase 2/3 trial in non-hospitalized patients with mild-moderate COVID-19 infections. It is the first polyclonal antibody therapeutic included in the ACTIV-2 master protocol, a study sponsored, funded and conducted by the National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH).\n\n“These promising in vitro data show that SAB-185 can neutralize SARS-CoV-2 spike-containing viruses, including those with mutations present in some variants of concern and accordingly represents an encouraging potential treatment for COVID-19,” said Sean Whelan, PhD, lead study investigator and Head of the Department of Molecular Microbiology, Washington University School of Medicine in St. Louis. “SAB-185 demonstrates effective neutralization of SARS-CoV-2 spike-containing viruses that have substitutions S477N, E484K, and N501Y, which have been implicated in COVID-19 outbreaks and surges in a number of countries and result in resistance to some antibodies.”\n\nIn the study, researchers conducted SAB-185 neutralization assays with multiple mutant SARS-CoV-2 pseudovirus strains, including sequences present in recently mutated strains that have emerged as a global concern. SAB-185 retained its neutralization potency for variants of recent concern. Importantly, compared to monoclon...